Invivyd (NASDAQ:IVVD) Price Target Cut to $1.00 by Analysts at D. Boral Capital

Key Points

• D. Boral Capital has lowered its price target for Invivyd (IVVD) from $3.00 to $1.00, although they maintain a "buy" rating on the stock, suggesting a potential upside of nearly 92.27% from current levels.
• HC Wainwright has reissued a "buy" rating with a higher target of $5.00, indicating differing opinions among analysts about Invivyd's future performance.
• Invivyd reported a loss of ($0.12) EPS for the latest quarter, missing estimates, and generated only $11.79 million in revenue against expectations of $23.16 million.

Invivyd (NASDAQ:IVVD - Get Free Report) had its price objective decreased by stock analysts at D. Boral Capital from $3.00 to $1.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. D. Boral Capital's price objective would indicate a potential upside of 92.27% from the stock's current price.

Separately, HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Invivyd in a report on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $3.18.

Invivyd Price Performance

IVVD stock opened at $0.5201 on Monday. Invivyd has a 1-year low of $0.3546 and a 1-year high of $2.74. The firm has a fifty day moving average price of $0.73 and a two-hundred day moving average price of $0.81. The firm has a market cap of $62.48 million, a price-to-earnings ratio of -0.57 and a beta of 0.51.

Invivyd (NASDAQ:IVVD - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.08). Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%.The business had revenue of $11.79 million during the quarter, compared to the consensus estimate of $23.16 million. As a group, analysts expect that Invivyd will post -1.64 EPS for the current fiscal year.

Insider Activity

In related news, insider Jill Andersen sold 49,402 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $0.57, for a total value of $28,159.14. Following the completion of the transaction, the insider directly owned 84,446 shares of the company's stock, valued at $48,134.22. This represents a 36.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 277,654 shares of company stock worth $167,215 in the last three months. Insiders own 25.40% of the company's stock.

Institutional Trading of Invivyd

Several hedge funds have recently added to or reduced their stakes in the business. Mithril II GP LP bought a new stake in shares of Invivyd during the fourth quarter valued at about $4,981,000. AQR Capital Management LLC grew its position in Invivyd by 2,051.0% in the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company's stock valued at $249,000 after buying an additional 391,617 shares in the last quarter. Two Sigma Advisers LP increased its stake in Invivyd by 1,276.5% during the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company's stock valued at $135,000 after buying an additional 282,100 shares during the period. Deutsche Bank AG raised its position in shares of Invivyd by 35.2% during the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock worth $385,000 after buying an additional 227,463 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Invivyd in the 2nd quarter worth approximately $158,000. Institutional investors own 70.36% of the company's stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.